argenx SE Announces Advancement of ARGX-119 to Registrational Study for Congenital Myasthenic Syndromes Following Promising Phase 1b Results
argenx SE has announced the advancement of ARGX-119 to a registrational study for congenital myasthenic syndromes (CMS) after positive Phase 1b results. The study showed a favorable safety profile and met its primary endpoint, with improvements noted in secondary endpoints such as the Six-Minute Walk Test and Myasthenia Gravis scores in treated DOK7-CMS patients. Detailed results will be presented at an upcoming medical meeting.
argenx SE, a global immunology company, has announced the advancement of its clinical development program for ARGX-119, a first-in-class agonist antibody targeting muscle-specific kinase (MuSK), intended for use in patients with congenital myasthenic syndromes (CMS). This decision follows the analysis of topline data from a Phase 1b study, which demonstrated a favorable safety and tolerability profile, meeting the primary endpoint of the trial. The study also evaluated efficacy across multiple secondary and exploratory endpoints, including the Six-Minute Walk Test, Quantitative Myasthenia Gravis score, and Myasthenia Gravis Activities of Daily Living score, with consistent improvements observed in treated DOK7-CMS patients over the 12-week period. Detailed results from the study are scheduled to be presented at an upcoming medical meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. arGEN-X SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001115246-en) on June 30, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
